|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-2-26
|
|
pubmed:abstractText |
Gimatecan is an orally bioavailable camptothecin analogue with preclinical findings of promising antitumor activity. A phase I design of concerted dose escalation and dosing duration was implemented to assess the potential schedule dependency of tolerability that emerged from animal studies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BaselgaJJ,
pubmed-author:CapriGG,
pubmed-author:CarminatiPP,
pubmed-author:CernyTT,
pubmed-author:CrestaSS,
pubmed-author:D'IncalciMM,
pubmed-author:GattiBB,
pubmed-author:GianniLL,
pubmed-author:HessDD,
pubmed-author:MalossiAA,
pubmed-author:MarsoniSS,
pubmed-author:Rota CaremoliEE,
pubmed-author:SessaCC,
pubmed-author:TriggRR,
pubmed-author:ZaniboniAA,
pubmed-author:ZannaCC,
pubmed-author:ZucchettiMM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
561-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17150998-Administration, Oral,
pubmed-meshheading:17150998-Adult,
pubmed-meshheading:17150998-Aged,
pubmed-meshheading:17150998-Aged, 80 and over,
pubmed-meshheading:17150998-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:17150998-Camptothecin,
pubmed-meshheading:17150998-Dose-Response Relationship, Drug,
pubmed-meshheading:17150998-Drug Administration Schedule,
pubmed-meshheading:17150998-Europe,
pubmed-meshheading:17150998-Female,
pubmed-meshheading:17150998-Half-Life,
pubmed-meshheading:17150998-Humans,
pubmed-meshheading:17150998-Male,
pubmed-meshheading:17150998-Middle Aged,
pubmed-meshheading:17150998-Neoplasms,
pubmed-meshheading:17150998-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.
|
|
pubmed:affiliation |
Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
